← Leaderboards
David Zarling
Colby Pharmaceutical Company
$1,499,978
Attributed
$1,499,978
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,499,978 · 1
By mechanism
N01$1,499,978 · 1
Top collaborators
No co-investigators on record.
Most similar at Colby Pharmaceutical Company
Same institution · by research overlap
- Jeffery Fairman$249,997
Others in their field
Top investigators on “Adverse Effects”
- James Dennis Neaton · Northwestern University$203,539,316
- John M Lachin · George Washington University$139,991,329
- Elizabeth A Thom · George Washington University$126,101,581
- David M Nathan · Massachusetts Institute Of Technology$120,651,895
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,102,044
Research focus
Adverse EffectsBasic ScienceClinical TrialsComplicationContractsCyclic GmpDoseDose-LimitingEsophagealEsophagitisEsophagusHead And Neck CancerHead And Neck Cancer PatientHuman Sod2 ProteinMedicalMouse ModelMouthwashMucositisNormal Tissue MorphologyOral MucositisPreventProgramsProphylacticRadiation